DGAP-Ad hoc: MOLOGEN AG

DGAP-Adhoc: MOLOGEN completes portfolio review: shift from research to product- and market-oriented company

MOLOGEN AG / Key word(s): Strategic Company Decision

09.06.2016 11:28

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc notification according to § 15 WpHG

MOLOGEN completes portfolio review: shift from research to product- and market-oriented company

Berlin, 09 June 2016 - Today, the Executive Board of MOLOGEN AG (ISIN DE0006637200/WKN 663720), with the consent of the supervisory board, decided to implement a strategy program to concentrate its business activities on the further development and commercialisation of its main product, i.e. lefitolimod (MGN1703) including the successor molecule EnanDIM(R). In future, the main focus of the company will be (i) on continuing the four clinical studies on lefitolimod (MGN1703) concerning the indications colorectal cancer, small-cell lung cancer and HIV as well as (ii) on an upcoming combination study on the immunotherapy Yervoy(R) (ipilimumab) in patients with advanced solid tumours. In order to prepare the production of large quantities of the compound lefitolimod (MGN1703) to meet potential market demands, MOLOGEN AG plans to outsource its production activities to a specialist contract manufacturer which is still to be chosen.

In contrast, MOLOGEN AG will shelve any further development of the compound MGN1601, a cell-based therapeutic vaccine against renal cancer, for the time being. In addition and depending on market conditions, the company plans to partly or completely dispose of the MIDGE(R) platform technology, which has been specially developed for the treatment of infectious diseases, including the early phase product candidates MGN1331, a compound against leishmaniasis, MGN1333, a compound against hepatitis B and MGN1404, a compound against malignant melanoma. In the course of this concentration on more market orientated products, which have overcome the status of basic research already, MOLOGEN AG envisages further adjustments to the business organisation. Thus, research activities previously carried out within the company will mostly be discontinued. Further development will be performed by research service providers and in the context of cooperations. These measures of concentration will reduce the staff of MOLOGEN by approximately a quarter.

The implementation of the new structure is expected to be completed by the end of 2016. The measures will not have a material impact on the financial planning of the company. Until final data from the ongoing trial IMPALA is available, presumably in the second half of 2018, MOLOGEN AG currently still estimates unaltered financing needs which exceed the existing liquidity and which have to be covered to complete the IMPALA trial.

The Executive Board will present the strategic program to shareholders at the annual shareholders' meeting which is now scheduled for 11 August 2016. In order to meet the financing needs, it is likely that the shareholders' meeting will be asked to approve a cash capital increase with subscription rights.

- End of the ad-hoc notification -

DISCLAIMER This announcement does not constitute an offer to buy shares or other securities of MOLOGEN AG and does not replace the prospectus. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the "United States"), Australia, Canada or Japan or in any jurisdiction. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. There will be no public offer of the securities in the United States. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com

Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

09.06.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap.de

--------------------------------------------------------------------------- Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------